Pasar al contenido principal

IDENTIFICACION DE NUEVAS DIANAS TERAPEUTICAS EN DEMENCIA

PID2020-115613RA-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2020
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario FUNDACION UNIVERSITARIA SAN PABLO CEU

Resultados relacionados

Resultados totales (Incluyendo duplicados): 4
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

A genetic and proteomic comparison of key AD biomarkers across tissues

  • Marsh, Thomas W.
  • Western, Daniel|||0000-0003-3725-9553
  • Timsina, Jigyasha
  • Gorijala, Priyanka
  • Yang, Chengran
  • Pastor, Pau|||0000-0002-7493-8777
  • Liu, Menghan
  • Morris, John C.|||0000-0001-9820-5618
  • Bateman, Randall J.
  • Schindler, Suzanne E.
  • Sung, Yun Ju
  • Cruchaga, Carlos|||0000-0002-0276-2899
INTRODUCTION: Plasma has been proposed as an alternative to cerebrospinal fluid (CSF) for measuring Alzheimer's disease (AD) biomarkers, but no studies have analyzed in detail which biofluid is more informative for genetics studies of AD. METHOD: Eleven proteins associated with AD (α-synuclein, apolipoprotein E [apoE], CLU, GFAP, GRN, NfL, NRGN, SNAP-25, TREM2, VILIP-1, YKL-40) were assessed in plasma (n = 2317) and CSF (n = 3107). Both plasma and CSF genome-wide association study (GWAS) analyses were performed for each protein, followed by functional annotation. Additional characterization for each biomarker included calculation of correlations and predictive power. RESULTS: Eighteen plasma protein quantitative train loci (pQTLs) associated with 10 proteins and 16 CSF pQTLs associated with 9 proteins were identified. Plasma and CSF shared some genetic loci, but protein levels between tissues correlated weakly. CSF protein levels better associated with AD compared to plasma. DISCUSSION: The present results indicate that CSF is more informative than plasma for genetic studies in AD. Highlights: The identification of novel protein quantitative trait loci (pQTLs) in both plasma and cerebrospinal fluid (CSF). Plasma and CSF levels of neurodegeneration-related proteins correlated weakly. CSF is more informative than plasma for genetic studies of Alzheimer's disease (AD). Neurofilament light (NfL), triggering receptor expressed on myeloid cells 2 (TREM2), and chitinase-3-like protein 1 (YKL-40) tend to show relatively strong inter-tissue associations. A novel signal in the apolipoprotein E (APOE) region was identified, which is an eQTL for APOC1.
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

CSF proteins of inflammation, proteolysis and lipid transport define preclinical AD and progression to AD dementia in cognitively unimpaired individuals

  • Campo, Marta del
  • Quesada, Carlos
  • Vermunt, Lisa
  • Peeters, Carel F. W.
  • Hok-A-Hin, Yanaika S.
  • Trieu, Calvin
  • den Braber, Anouk
  • Verberk, Inge M. W.
  • Visser, Pieter Jelle
  • Tijms, Betty M.
  • van der Flier, Wiesje M.
  • Teunissen, Charlotte E.
This preclinical AD CSF proteome study identified a panel of 12-CSF markers detecting amyloid positivity and clinical progression to AD with high accuracy; some of these CSF proteins related to immune function, neurotrophic processes, energy metabolism and endolysosomal functioning (e.g., ITGB2, CLEC5A, IGFBP-1, CST3) changed before amyloid positivity is established., This research is part of the neurodegeneration research program of Amsterdam Neuroscience. Alzheimer Center Amsterdam is supported by Stichting Alzheimer Nederland and Stichting VUmc fonds. The chair Wiesje van der Flier is supported by the Pasman stichting. This study was supported by Alzheimer Nederland (CT, MC), ZonMW (#73305095007), Health ~ Holland, Topsector Life Sciences & Health (PPP-allowance; #LSHM20106). MC is supported by the attraction talent fellowship of Comunidad de Madrid (2018-T2/BMD-11885) and "PROYECTOS I + D + I - 2020"- Retos de investigación from the Ministerio Español de Ciencia e innovación (PID2020-115613RA-I00). The SCIENCe study has received funding from Gieskes-Strijbis Fonds and Stichting Dioraphte. WF and CT are recipient of TAP-Dementia, a ZonMW funded project (#10510032120003) under the Dutch National Dementia Strategy.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

CSF proteins of inflammation, proteolysis and lipid transport define preclinical AD and progression to AD dementia in cognitively unimpaired individuals

  • Campo, Marta del
  • Quesada, Carlos
  • Vermunt, Lisa
  • Peeters, Carel F. W.
  • Hok-A-Hin, Yanaika S.
  • Trieu, Calvin
  • den Braber, Anouk
  • Verberk, Inge M. W.
  • Visser, Pieter Jelle
  • Tijms, Betty M.
  • van der Flier, Wiesje M.
  • Teunissen, Charlotte E.
This preclinical AD CSF proteome study identified a panel of 12-CSF markers detecting amyloid positivity and clinical progression to AD with high accuracy; some of these CSF proteins related to immune function, neurotrophic processes, energy metabolism and endolysosomal functioning (e.g., ITGB2, CLEC5A, IGFBP-1, CST3) changed before amyloid positivity is established., This research is part of the neurodegeneration research program of Amsterdam Neuroscience. Alzheimer Center Amsterdam is supported by Stichting Alzheimer Nederland and Stichting VUmc fonds. The chair Wiesje van der Flier is supported by the Pasman stichting. This study was supported by Alzheimer Nederland (CT, MC), ZonMW (#73305095007), Health ~ Holland, Topsector Life Sciences & Health (PPP-allowance; #LSHM20106). MC is supported by the attraction talent fellowship of Comunidad de Madrid (2018-T2/BMD-11885) and "PROYECTOS I + D + I - 2020"- Retos de investigación from the Ministerio Español de Ciencia e innovación (PID2020-115613RA-I00). The SCIENCe study has received funding from Gieskes-Strijbis Fonds and Stichting Dioraphte. WF and CT are recipient of TAP-Dementia, a ZonMW funded project (#10510032120003) under the Dutch National Dementia Strategy.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

CSF proteome profiling reveals biomarkers to discriminate dementia with Lewy bodies from Alzheimer's disease

  • Campo Milán, Marta del|||0000-0003-2808-3699
  • Vermunt, Lisa
  • Peeters, Carel F.W.
  • Sieben, Anne|||0000-0003-1278-6605
  • Hok-A-Hin, Yanaika S.|||0000-0001-9713-116X
  • Lleó, Alberto|||0000-0002-2568-5478
  • Alcolea, Daniel|||0000-0002-3819-3245
  • van Nee, Mirrelijn
  • Engelborghs, Sebastiaan|||0000-0003-0304-9785
  • van Alphen, Juliette L.
  • Arezoumandan, Sanaz
  • Chen-Plotkin, Alice
  • Irwin, David J.|||0000-0002-5599-5098
  • van der Flier, Wiesje M.|||0000-0001-8766-6224
  • Lemstra, Afina W.|||0000-0002-8933-3260
  • Teunissen, Charlotte E.|||0000-0002-4061-0837
Diagnosis of dementia with Lewy bodies (DLB) is challenging and specific biofluid biomarkers are highly needed. We employed proximity extension-based assays to measure 665 proteins in the cerebrospinal fluid (CSF) from patients with DLB (n = 109), Alzheimer's disease (AD, n = 235) and cognitively unimpaired controls (n = 190). We identified over 50 CSF proteins dysregulated in DLB, enriched in myelination processes among others. The dopamine biosynthesis enzyme DDC was the strongest dysregulated protein, and could efficiently discriminate DLB from controls and AD (AUC:0.91 and 0.81 respectively). Classification modeling unveiled a 7-CSF biomarker panel that better discriminate DLB from AD (AUC:0.93). A custom multiplex panel for six of these markers (DDC, CRH, MMP-3, ABL1, MMP-10, THOP1) was developed and validated in independent cohorts, including an AD and DLB autopsy cohort. This DLB CSF proteome study identifies DLB-specific protein changes and translates these findings to a practicable biomarker panel that accurately identifies DLB patients, providing promising diagnostic and clinical trial testing opportunities.